Strontium Chloride 89 – Cancer Metastases to Bone

Non-Narcotic Pain Palliation for Cancer Metastases to the Bone

Generic Strontium Chloride Sr-89 Injection USP (Strontium-89) is a radioactive pharmaceutical injection to relieve bone pain in patients with painful skeletal metastases. In the body, Strontium acts similar to calcium and is preferentially taken up in osteoblastic tissue while the unabsorbed isotope is excreted in the urine the first 2 to 3 days following injection, clearing rapidly from the blood and selectively localizing in bone mineral. Uptake of strontium by bone occurs preferentially in sites of active osteogenesis; thus primary bone tumors and areas of metastatic involvement (blastic lesions) can accumulate significantly greater concentrations of strontium than surrounding normal bone.

Generic Strontium Chloride Sr-89 Injection USP can be used in combination with opiate based drugs like Oxycotin®, Morphine, Percocet® as well as cancer therapeutic drugs. Clinical studies have demonstrated that the combination of alternating weekly chemohormonal therapies with Sr-89 demonstrated a prolonged progression-free and overall survival with acceptable toxicity.

Generic Strontium-89 injection is a pure beta emitter, and selectively irradiates sites of primary and metastatic bone involvement with minimal irradiation of soft tissues distant from bone lesions. The presence of bone metastases should be confirmed prior to therapy.

When blastic osseous metastases are present, significantly enhanced localization of the radiopharmaceutical will occur with corresponding higher doses to the metastases compared with normal bones and other organs. Although responses can vary, pain relief typically beginning 7 to 20 days after injection and lasts for months. Uptake of strontium by bone occurs preferentially in sites of active osteogenesis; thus primary bone tumors and areas of metastatic involvement (blastic lesions) can accumulate significantly greater concentrations of strontium than surrounding normal bone.

 

 

 

 

September 7, 2016

Q BioMed Inc. (OTCQB: QBIO), a biotechnology acceleration company is pleased to announce the closing of an exclusive license and option agreement for a FDA approved generic drug, Strontium Chloride (“SR89”).

 

“We are very excited about the potential for this drug and look forward to bringing it to market as quickly as possible, delivering significant value to all stakeholders, including current and future patients. The revenue we hope to realize will be a significant milestone for us and substantially derisks our business. However, over and above the near term revenue, we are particularly enthusiastic about the opportunities for growth to increase the potential revenue exponentially.”  – Denis Corin CEO Q BioMed Inc.

Social media & sharing icons powered by UltimatelySocial